748904
Last Update Posted: 2022-02-08
Recruiting has ended
All Genders accepted | 18 Years-65 Years |
0 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Rifaximin Versus Lactulose in Renal Failure
The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.
Eligibility
Relevant conditions:
Liver Cirrhosis
Renal Failure
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
Inclusion criteria
Exclusion criteria
locations
Data sourced from ClinicalTrials.gov